| Literature DB >> 17251291 |
Sigrid Hatse1, Dana Huskens, Katrien Princen, Kurt Vermeire, Gary J Bridger, Erik De Clercq, Mette M Rosenkilde, Thue W Schwartz, Dominique Schols.
Abstract
The chemokine receptor CXCR3 can exhibit weak coreceptor function for several human immunodeficiency virus type 1 (HIV-1) and HIV-2 strains and clinical isolates. These viruses produced microscopically visible cytopathicity in U87.CD4.CXCR3 cell cultures, whereas untransfected (CXCR3-negative) U87.CD4 cells remained uninfected. Depending on the particular virus, the coreceptor efficiency of CXCR3 was 100- to >10,000-fold lower compared to that of CXCR4. A CXCR3 variant carrying the CXCR4 binding pocket was constructed by simultaneous lysine-to-alanine and serine-to-glutamate substitutions at positions 300 and 304 of the CXCR3 receptor. This mutant receptor (CXCR3[K300A, S304E]) showed markedly enhanced HIV coreceptor function compared to the wild-type receptor (CXCR3[WT]). Moreover, the CXCR4 antagonist AMD3100 exhibited antagonistic and anti-HIV activities in U87.CD4.CXCR3[K300A, S304E] cells but not in U87.CD4.CXCR3[WT] cells.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17251291 PMCID: PMC1866035 DOI: 10.1128/JVI.01941-06
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103